Modelling in economic evaluations of medicines
Modelovanje u farmakoekonomskim evaluacijama lekova
Article (Published version)
Metadata
Show full item recordAbstract
Economic evaluation in health (also known as pharmacoeconomic in case of medicines)
identifies, measures, and values costs and outcomes of alternative healthcare technologies, and
can be performed alongside controlled clinical trials, but analytical modelling is usually used.
Decision trees and Markov models are the two most common approaches used in economic
evaluation. The biggest advantages of a decision tree are clarity, simplicity, and
straightforwardness. On the other hand, the main advantage of the Markov model is its ability to
incorporate complex events into the simulation, which is practically impossible to do with a
decision tree. Reimbursement policy in Serbia mandatorily incorporates economic evaluations to
promote availability and accessibility of the prescription medicines. To show current
pharmacoeconomic value of a medicine, budget impact analysis and the cost-effectiveness
analysis should be included. The latter should be conducted using appropriate modellin...g
techniques. However, since no official methodological guidelines about the modelling and
economic analysis exist, the submissions by marketing authorization holders vary greatly. The
future of pharmacoeconomic modelling depends on the research area of interest, with new
frameworks and approaches being developed.
Ekonomske evaluacije u zdravstvu (ili farmakoekonomija u slučaju lekova) identifikuju, vrednuju i mere troškove i ishode alternativnih zdravstvenih tehnologija, i mogu se sprovoditi paralelno sa kliničkim studijama, ali se češće primenjuje modelovanje. Drvo odlučivanja i Markovljev model su dva najčešće korišćena modela u ekonomskim evaluacijama. Najveća prednost primene drveta odlučivanja je njegova jednostavnost, jasnoća i direktnost. Sa druge strane, najveća prednost Markovljevog modela je sposobnost da uključi kompleksne događaje u simulaciju, što je praktično nemoguće sa drvetom odlučivanja. Ekonomske evaluacije su obavezan zahtev u nekoliko procesa u cilju povećanja dostupnosti lekova u Srbiji. Kako bi se pokazala sadašnja farmakoekonomska prednost leka neophodno je sprovesti analizu uticaja na budžet i analizu troškovne isplativosti. Drugu analizu je neophodno sprovesti primenom odgovarajuće tehnike modelovanja. Međutim, kako ne postoje zvanične smernice o modelovanju i ekonomsk...im evaluacija, dokumentacija podneta od strane nosioca dozvole pokazuje značajno variranje. Budućnost modelovanja u farmakoekonomiji zavisi od istraživačkog interesa, pri čemu se razvijaju novi okviri i pristupi.
Keywords:
Economic evaluation / modelling / decision tree / Markov model / farmakoekonomske evaluacije / modelovanje / drvo odlučivanja / Markovljev modelSource:
Arhiv za farmaciju, 2021, 71, 4, 354-364Publisher:
- Beograd : Savez farmaceutskih udruženja Srbije
Collections
Institution/Community
PharmacyTY - JOUR AU - Lakić, Dragana AU - Stević, Ivana AU - Odalović, Marina AU - Tadić, Ivana PY - 2021 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3961 AB - Economic evaluation in health (also known as pharmacoeconomic in case of medicines) identifies, measures, and values costs and outcomes of alternative healthcare technologies, and can be performed alongside controlled clinical trials, but analytical modelling is usually used. Decision trees and Markov models are the two most common approaches used in economic evaluation. The biggest advantages of a decision tree are clarity, simplicity, and straightforwardness. On the other hand, the main advantage of the Markov model is its ability to incorporate complex events into the simulation, which is practically impossible to do with a decision tree. Reimbursement policy in Serbia mandatorily incorporates economic evaluations to promote availability and accessibility of the prescription medicines. To show current pharmacoeconomic value of a medicine, budget impact analysis and the cost-effectiveness analysis should be included. The latter should be conducted using appropriate modelling techniques. However, since no official methodological guidelines about the modelling and economic analysis exist, the submissions by marketing authorization holders vary greatly. The future of pharmacoeconomic modelling depends on the research area of interest, with new frameworks and approaches being developed. AB - Ekonomske evaluacije u zdravstvu (ili farmakoekonomija u slučaju lekova) identifikuju, vrednuju i mere troškove i ishode alternativnih zdravstvenih tehnologija, i mogu se sprovoditi paralelno sa kliničkim studijama, ali se češće primenjuje modelovanje. Drvo odlučivanja i Markovljev model su dva najčešće korišćena modela u ekonomskim evaluacijama. Najveća prednost primene drveta odlučivanja je njegova jednostavnost, jasnoća i direktnost. Sa druge strane, najveća prednost Markovljevog modela je sposobnost da uključi kompleksne događaje u simulaciju, što je praktično nemoguće sa drvetom odlučivanja. Ekonomske evaluacije su obavezan zahtev u nekoliko procesa u cilju povećanja dostupnosti lekova u Srbiji. Kako bi se pokazala sadašnja farmakoekonomska prednost leka neophodno je sprovesti analizu uticaja na budžet i analizu troškovne isplativosti. Drugu analizu je neophodno sprovesti primenom odgovarajuće tehnike modelovanja. Međutim, kako ne postoje zvanične smernice o modelovanju i ekonomskim evaluacija, dokumentacija podneta od strane nosioca dozvole pokazuje značajno variranje. Budućnost modelovanja u farmakoekonomiji zavisi od istraživačkog interesa, pri čemu se razvijaju novi okviri i pristupi. PB - Beograd : Savez farmaceutskih udruženja Srbije T2 - Arhiv za farmaciju T1 - Modelling in economic evaluations of medicines T1 - Modelovanje u farmakoekonomskim evaluacijama lekova VL - 71 IS - 4 SP - 354 EP - 364 DO - 10.5937/arhfarm71-32404 ER -
@article{ author = "Lakić, Dragana and Stević, Ivana and Odalović, Marina and Tadić, Ivana", year = "2021", abstract = "Economic evaluation in health (also known as pharmacoeconomic in case of medicines) identifies, measures, and values costs and outcomes of alternative healthcare technologies, and can be performed alongside controlled clinical trials, but analytical modelling is usually used. Decision trees and Markov models are the two most common approaches used in economic evaluation. The biggest advantages of a decision tree are clarity, simplicity, and straightforwardness. On the other hand, the main advantage of the Markov model is its ability to incorporate complex events into the simulation, which is practically impossible to do with a decision tree. Reimbursement policy in Serbia mandatorily incorporates economic evaluations to promote availability and accessibility of the prescription medicines. To show current pharmacoeconomic value of a medicine, budget impact analysis and the cost-effectiveness analysis should be included. The latter should be conducted using appropriate modelling techniques. However, since no official methodological guidelines about the modelling and economic analysis exist, the submissions by marketing authorization holders vary greatly. The future of pharmacoeconomic modelling depends on the research area of interest, with new frameworks and approaches being developed., Ekonomske evaluacije u zdravstvu (ili farmakoekonomija u slučaju lekova) identifikuju, vrednuju i mere troškove i ishode alternativnih zdravstvenih tehnologija, i mogu se sprovoditi paralelno sa kliničkim studijama, ali se češće primenjuje modelovanje. Drvo odlučivanja i Markovljev model su dva najčešće korišćena modela u ekonomskim evaluacijama. Najveća prednost primene drveta odlučivanja je njegova jednostavnost, jasnoća i direktnost. Sa druge strane, najveća prednost Markovljevog modela je sposobnost da uključi kompleksne događaje u simulaciju, što je praktično nemoguće sa drvetom odlučivanja. Ekonomske evaluacije su obavezan zahtev u nekoliko procesa u cilju povećanja dostupnosti lekova u Srbiji. Kako bi se pokazala sadašnja farmakoekonomska prednost leka neophodno je sprovesti analizu uticaja na budžet i analizu troškovne isplativosti. Drugu analizu je neophodno sprovesti primenom odgovarajuće tehnike modelovanja. Međutim, kako ne postoje zvanične smernice o modelovanju i ekonomskim evaluacija, dokumentacija podneta od strane nosioca dozvole pokazuje značajno variranje. Budućnost modelovanja u farmakoekonomiji zavisi od istraživačkog interesa, pri čemu se razvijaju novi okviri i pristupi.", publisher = "Beograd : Savez farmaceutskih udruženja Srbije", journal = "Arhiv za farmaciju", title = "Modelling in economic evaluations of medicines, Modelovanje u farmakoekonomskim evaluacijama lekova", volume = "71", number = "4", pages = "354-364", doi = "10.5937/arhfarm71-32404" }
Lakić, D., Stević, I., Odalović, M.,& Tadić, I.. (2021). Modelling in economic evaluations of medicines. in Arhiv za farmaciju Beograd : Savez farmaceutskih udruženja Srbije., 71(4), 354-364. https://doi.org/10.5937/arhfarm71-32404
Lakić D, Stević I, Odalović M, Tadić I. Modelling in economic evaluations of medicines. in Arhiv za farmaciju. 2021;71(4):354-364. doi:10.5937/arhfarm71-32404 .
Lakić, Dragana, Stević, Ivana, Odalović, Marina, Tadić, Ivana, "Modelling in economic evaluations of medicines" in Arhiv za farmaciju, 71, no. 4 (2021):354-364, https://doi.org/10.5937/arhfarm71-32404 . .